ReviewApoptosis : an international journal on programmed cell death2026
Endothelial cell heterogeneity drives angiogenesis in endometriosis: mechanisms and emerging organoid-based models.
Review in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Endometriosis (EMs) is characterized by the establishment and persistence of ectopic lesions, a process fundamentally dependent on aberrant angiogenesis. Endothelial cells (ECs) play a central role in this process; however, accumulating evidence indicates that ECs are not a homogeneous population but comprise multiple subtypes with distinct molecular signatures and functional states, including quiescent, proliferative, hormone-responsive and inflammation-associated phenotypes. The initiation and maintenance of pathological angiogenesis in EMs are coordinately regulated by hormonal signaling, inflammatory responses and immune modulation, which collectively determine vascular remodeling and lesion sustainability. Despite significant advances, mechanistic insights into EMs-associated angiogenesis have been limited by the lack of physiologically relevant experimental models. Conventional two-dimensional culture systems fail to recapitulate the complex three-dimensional cellular interactions, whereas animal models are constrained by interspecies differences. Recent progress in stem cell biology, extracellular matrix (ECM) engineering and microfluidic technologies has enabled the development of organoid-based platforms that more faithfully reconstruct the EMs microenvironment. When integrated with functional biomaterials possessing tunable mechanical properties and bioactivity, these systems allow precise modulation of endothelial behaviors, including proliferation, migration and lumen formation, through controlled delivery of angiogenic cues. In this Review, we summarize recent advances in biomaterial-supported organoid systems for dissecting endothelial cell heterogeneity and its contribution to aberrant angiogenesis in EMs. We further discuss their emerging roles in mechanistic studies and the development of targeted therapeutic strategies.
Indexed as
Identifiers
42622720What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.